Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25667
Title: Complete recovery from COVID-19 of a kidney-pancreas transplant recipient: potential benefit from everolimus?
Austin Authors: Heron, Vanessa C ;Bach, Cindy-Anne T;Holmes, Natasha E ;Whitlam, John B 
Affiliation: Nephrology
General Medicine
Infectious Diseases
Issue Date: 11-Jan-2021
Date: 2021
Publication information: BMJ Case Reports 2021; 14(1): e238413
Abstract: We present a kidney-pancreas transplant recipient who achieved complete recovery from COVID-19. A 45-year-old patient with T3 paraplegia underwent kidney-pancreas transplantation 18 years ago, followed by a subsequent kidney transplant 9 years ago, and presented with fever, hypoxia and hypotension after exposure to two confirmed cases of COVID-19. History of solid organ transplant, pre-existing renal impairment, asthma and an elevated D-dimer were identified as established risk factors for severe COVID-19. Supportive management was provided, baseline immunosuppression with everolimus was continued, and oral prednisolone was increased. A complete recovery was observed. Given the favourable outcome despite risk factors for severe COVID-19, we identify and review the potential mitigating roles of immunosuppression and mammalian target of rapamycin (mTOR) inhibitors in this disease. Further investigation is required to establish whether mTOR inhibitors could be used as therapeutic agents to treat COVID-19, or as alternative immunosuppression implemented early in the COVID-19 disease course.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25667
DOI: 10.1136/bcr-2020-238413
ORCID: 0000-0002-7659-6264
0000-0001-8501-4054
0000-0003-2202-1462
Journal: BMJ Case Reports
PubMed URL: 33431539
Type: Journal Article
Subjects: drugs: infectious diseases
renal transplantation
COVID-19
Appears in Collections:Journal articles

Show full item record

Page view(s)

118
checked on Dec 10, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.